MA38376A1 - Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer - Google Patents
Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancerInfo
- Publication number
- MA38376A1 MA38376A1 MA38376A MA38376A MA38376A1 MA 38376 A1 MA38376 A1 MA 38376A1 MA 38376 A MA38376 A MA 38376A MA 38376 A MA38376 A MA 38376A MA 38376 A1 MA38376 A1 MA 38376A1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- aad
- arginine
- treatment
- albumin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 102000009027 Albumins Human genes 0.000 title abstract 2
- 108010088751 Albumins Proteins 0.000 title abstract 2
- 108010082340 Arginine deiminase Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004475 Arginine Substances 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 235000019750 Crude protein Nutrition 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique contenant une protéine de fusion arginine déiminase de liaison à l'albumine (aad) pour le traitement du cancer ou d'autres maladies dépendantes de l'arginine. La protéine de fusion aad peut être purifiée à la fois à partir des fractions solubles et insolubles de protéines brutes, elle se lie à la sérum albumine humaine (hsa) et a son activité élevée avec une demi-vie plus longue pour l'élimination efficace de l'arginine dans des cellules cancéreuses. Les activités spécifiques d'adi et aad de type sauvage dans la présente invention sont de 8,4 et 8,2 u/mg (au ph physiologique de 7,4), respectivement. L'aad utilisée dans la présente invention peut être utilisée dans le traitement de divers cancers (par exemple le cancer du pancréas, la leucémie, le cancer de la tête et du cou, le cancer colorectal, le cancer du poumon, le cancer du sein, le cancer du foie, le cancer nasopharyngé, le cancer de l'œsophage, le cancer de la prostate, le cancer de l'estomac & le cancer du cerveau) et la guérison de maladies dépendantes de l'arginine. La composition peut être utilisée seule ou en combinaison avec au moins un agent chimiothérapeutique pour donner un effet synergique sur le traitement anticancéreux et/ou l'inhibition de la métastase.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773214P | 2013-03-06 | 2013-03-06 | |
| US14/197,236 US9255262B2 (en) | 2013-03-06 | 2014-03-05 | Albumin-binding arginine deminase and the use thereof |
| PCT/US2014/020943 WO2014138319A2 (fr) | 2013-03-06 | 2014-03-06 | Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38376A1 true MA38376A1 (fr) | 2017-10-31 |
| MA38376B1 MA38376B1 (fr) | 2019-03-29 |
Family
ID=51488086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38376A MA38376B1 (fr) | 2013-03-06 | 2014-03-06 | Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9255262B2 (fr) |
| EP (1) | EP2964761B1 (fr) |
| JP (1) | JP6243452B2 (fr) |
| KR (1) | KR102139844B1 (fr) |
| CN (1) | CN105142663B (fr) |
| AP (1) | AP2015008714A0 (fr) |
| AU (1) | AU2014225712C1 (fr) |
| BR (1) | BR112015021182A2 (fr) |
| CA (1) | CA2903152C (fr) |
| CL (1) | CL2015002479A1 (fr) |
| EA (1) | EA036064B1 (fr) |
| ES (1) | ES2909664T3 (fr) |
| IL (1) | IL240976A (fr) |
| MA (1) | MA38376B1 (fr) |
| MX (1) | MX379135B (fr) |
| MY (1) | MY175144A (fr) |
| PH (1) | PH12015501995A1 (fr) |
| SA (1) | SA515360970B1 (fr) |
| SG (1) | SG11201506679QA (fr) |
| TW (1) | TWI634212B (fr) |
| WO (1) | WO2014138319A2 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| EP3456700A1 (fr) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate |
| CN105985447B (zh) * | 2015-03-02 | 2019-10-22 | 四川大学华西医院 | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| CN104789489B (zh) * | 2015-03-09 | 2018-01-23 | 武汉远大弘元股份有限公司 | 一株高产精氨酸脱亚胺酶的蜡样芽孢杆菌及其应用 |
| EP3374504B1 (fr) * | 2015-11-09 | 2025-03-19 | CureVac SE | Molécules d'acide nucléique optimisées |
| WO2018136572A1 (fr) * | 2017-01-18 | 2018-07-26 | Savior Lifetec Corporation | Construction d'expression et procédé de production de protéines d'intérêt |
| EP3449935A1 (fr) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulée à l'intérieur des érythrocytes et leur utilisation dans le traitement du cancer et de la déficience en arginase-1 |
| US12508306B2 (en) | 2018-04-25 | 2025-12-30 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| AU2019275733B2 (en) | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| US20220363778A1 (en) * | 2019-08-28 | 2022-11-17 | The Research Foundation For The State University Of New York | Targeted delivery of tumor matrix modifying enzymes |
| CN111518851B (zh) * | 2019-11-06 | 2023-05-23 | 上海健康医学院 | 一种固定化酶连续制备[14/15n]-l-瓜氨酸的方法 |
| CN111394295B (zh) * | 2019-11-06 | 2023-03-10 | 上海健康医学院 | 一种制备固定化精氨酸脱亚胺酶及生产[14/15n]-l-瓜氨酸的方法 |
| US20210162028A1 (en) * | 2019-12-02 | 2021-06-03 | The Hong Kong Polytechnic University | Methods for Inducing Intermittent Fasting and Modulating Autophagy |
| EP4153167A4 (fr) * | 2020-06-29 | 2024-02-28 | Vision Global Holdings Limited | Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine |
| CA3196814A1 (fr) | 2020-09-25 | 2022-03-31 | Proabtech Inc. | Conjugue uricase-albumine, procede de preparation associe et son utilisation |
| EP4218825A4 (fr) * | 2020-09-25 | 2025-03-19 | Proabtech Inc. | Conjugué de variant polypeptidique fonctionnel et son utilisation |
| CN113584054B (zh) * | 2021-06-28 | 2023-04-18 | 河北远大九孚生物科技有限公司 | 编码精氨酸脱亚胺酶的dna分子及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2900279B2 (ja) * | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| US5196195A (en) * | 1990-03-27 | 1993-03-23 | Cornell Research Foundation, Inc. | Use of arginase to control nitric oxide formation |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5804183A (en) * | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) * | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
| GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| EP2213743A1 (fr) * | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| US20030157091A1 (en) | 2002-02-14 | 2003-08-21 | Dyax Corporation | Multi-functional proteins |
| CA2485169C (fr) | 2002-05-20 | 2013-03-26 | Joseph C. Mcauliffe | Derives de peptides et utilisation de ces derives pour la synthese de materiaux composites a base de silicium |
| HUE027902T2 (en) * | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| CN1292002C (zh) * | 2004-10-21 | 2006-12-27 | 北京双鹭药业股份有限公司 | 一种精氨酸脱酰酶融合蛋白、其制造方法及应用 |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| KR100934656B1 (ko) | 2006-02-06 | 2009-12-31 | 엘지전자 주식회사 | 다중 반송파 시스템에서의 무선 자원 할당 방법 |
| WO2007146038A2 (fr) * | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| EP2046820B1 (fr) | 2006-08-01 | 2010-10-20 | Pieris AG | Mutéines de lipocaline lacrymale et procédés permettant d'obtenir lesdites mutéines |
| EP2190863B1 (fr) * | 2007-07-31 | 2015-09-02 | Affibody AB | Nouvelles compositions, nouveaux procédés et nouvelles utilisations |
| EP2295560A1 (fr) * | 2009-09-14 | 2011-03-16 | RWTH Aachen University | Évolution dirigée de l'arginine déiminase pour une activité accrue à un pH physiologique |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
-
2014
- 2014-03-05 US US14/197,236 patent/US9255262B2/en not_active Ceased
- 2014-03-06 WO PCT/US2014/020943 patent/WO2014138319A2/fr not_active Ceased
- 2014-03-06 MY MYPI2015702796A patent/MY175144A/en unknown
- 2014-03-06 AP AP2015008714A patent/AP2015008714A0/xx unknown
- 2014-03-06 JP JP2015561630A patent/JP6243452B2/ja not_active Expired - Fee Related
- 2014-03-06 MA MA38376A patent/MA38376B1/fr unknown
- 2014-03-06 TW TW103107618A patent/TWI634212B/zh active
- 2014-03-06 BR BR112015021182A patent/BR112015021182A2/pt not_active Application Discontinuation
- 2014-03-06 EA EA201500826A patent/EA036064B1/ru not_active IP Right Cessation
- 2014-03-06 EP EP14760354.2A patent/EP2964761B1/fr not_active Not-in-force
- 2014-03-06 KR KR1020157027321A patent/KR102139844B1/ko not_active Expired - Fee Related
- 2014-03-06 SG SG11201506679QA patent/SG11201506679QA/en unknown
- 2014-03-06 CA CA2903152A patent/CA2903152C/fr active Active
- 2014-03-06 ES ES14760354T patent/ES2909664T3/es active Active
- 2014-03-06 CN CN201480012426.7A patent/CN105142663B/zh active Active
- 2014-03-06 MX MX2015011578A patent/MX379135B/es unknown
- 2014-03-06 AU AU2014225712A patent/AU2014225712C1/en not_active Ceased
-
2015
- 2015-09-01 IL IL240976A patent/IL240976A/en active IP Right Grant
- 2015-09-01 SA SA515360970A patent/SA515360970B1/ar unknown
- 2015-09-04 CL CL2015002479A patent/CL2015002479A1/es unknown
- 2015-09-08 PH PH12015501995A patent/PH12015501995A1/en unknown
- 2015-12-28 US US14/981,855 patent/US9803185B2/en not_active Ceased
-
2017
- 2017-07-25 US US15/658,685 patent/USRE47233E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38376B1 (fr) | Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer | |
| UA115648C2 (uk) | Доставка терапевтичних агентів до цнс | |
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| NZ702808A (en) | Methods and compositions for cns delivery of iduronate-2-sulfatase | |
| US20250268993A1 (en) | Alkaline phosphate-based oncology treatments | |
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| BR112023023463A2 (pt) | Inibidores da interação menin-mll | |
| US20200031928A1 (en) | Methods to manipulate alpha-fetoprotein (afp) | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| WO2008127680A3 (fr) | Diagnostic et traitement de maladies causées par des protéines mal pliées | |
| EP3193906A1 (fr) | Utilisation d'inhibiteurs de traitement protéolytique de il-36 pour le traitement et/ou la réduction d'une inflammation | |
| JP7749186B2 (ja) | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 | |
| US20220024991A1 (en) | Engineered flagellin-derived compositions and uses | |
| Øverbye et al. | Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain | |
| MY207979A (en) | Combination of chemotherapy with recombinant s. rolfsii lectin | |
| WO2017050240A1 (fr) | Méthode de traitement du cancer utilisant un dépléteur de l'arginine et un inhibiteur de l'ornithine décarboxylase (odc) | |
| ZA202401042B (en) | Protein compositions for the treatment of inflammatory diseases | |
| MA33668B1 (fr) | Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer | |
| TH169546A (th) | องค์ประกอบทางเภสัชกรรม ที่ประกอบรวมด้วย อาร์จินีนดีอิมิเนสที่จับกับอัลบูมิน (albumin-binding arginene deiminase) สำหรับการบำบัดที่ให้เป้าหมายไปที่มะเร็ง | |
| JP6170838B2 (ja) | 癌処置用ペプチド | |
| WO2016073733A1 (fr) | Méthodes de traitement du cancer à l'aide de lipopeptides | |
| AR124399A2 (es) | Formulaciones estables para la administración intratecal de iduranato-2-sulfatasa | |
| Krader | Study: Androgen inhibitor reduces death risk by 27%. | |
| TH173943A (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารกระทำการรักษาโรค ที่มีพื้นฐานมาจากฮีโมโกลบินที่ถูกโมดิฟายด์ (modified hemoglobin-based therapeutic agent) สำหรับการบำบัดที่ให้เป้าหมายไปที่มะเร็ง และการบันทึกภาพเพื่อวินิจฉัยโรค(diagnostic imaging) |